CYV Share Price Performance
AU$0.012
-0.00 (-25.00%)
98.0% undervalued intrinsic discount
AU$0.61
Fair Value
Price AU$0.012
Bailey AU$0.61
Fair ValueAU$0.61
Share Pricen/a
Ceryvyn Therapeutics Limited Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 51 Fair Values set on narratives written by author
CYV Community Narratives
BA
Fair Value
·Fair Value AU$0.61 98.0% undervalued intrinsic discount
Opthea Test
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Opthea Test
Opthea is testing a new add-on treatment for a common cause of vision loss that aims to help patients keep their sight for longer when used with today’s standard drugs. With late-stage trial results coming soon and big drugmakers already active in this area, the next year could decide whether this becomes a widely used new option—or a costly setback.Read more
Trending Discussion
Recently Updated Narratives
BA
Opthea Test
Fair Value: AU$0.61 98.0% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Ceryvyn Therapeutics Limited Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
- 0.22
- 100.00%
- -1,476,212.82%
- 0%
About CYV
- Founded
- 1984
- Employees
- n/a
- CEO
- WebsiteView website
Ceryvyn Therapeutics Limited, a clinical-stage biopharmaceutical company, researches and develops therapeutic products based on targeting vascular endothelial growth factors (VEGF) C, D and R3 in Australia and the United States. The company’s pipeline includes Sozinibercept, which is in phase 3 to treat wet age-related macular degeneration (Wet AMD), as well as in phase 2 to treat diabetic macular edema (DME). It serves the biotechnology and healthcare industries. The company was formerly known as Opthea Limited and changed its name to Ceryvyn Therapeutics Limited in July 2026. Ceryvyn Therapeutics Limited was incorporated in 1984 and is headquartered in Melbourne, Australia.
